Downtrend on the daily chart: below its 50- and 200-day averages · 50-day below the 200-day · SuperTrend down since Sep 21 · below the Ichimoku cloud · RSI 26 (oversold) · MACD below its signal · 9% above its 52-week low
| Investor | Value | Of portfolio | Shares | Change | Quarter |
|---|---|---|---|---|---|
| Renaissance Technologies | $386.8K | 0.00% | 50.30K | −15% | Q2 2026 |
From each investor's quarterly 13F filing with the SEC: positions at the quarter's end, reported up to 45 days later. All investors
No member of Congress has disclosed a TIL trade since 2025.
From House and Senate STOCK Act reports. Members disclose trades, not holdings, as value ranges up to 45 days later, so amounts are estimates and “last move” is a hint at who still holds it, not a position. All recent congress trades
| Date | Insider | Transaction | Shares | Value |
|---|---|---|---|---|
| Sep 9, 2025 | Laumas SandeepChief Financial Officer | Sale at price 23.04 - 23.88 per share. | 30K | $701.67K |
| Sep 9, 2025 | Laumas SandeepChief Financial Officer | Conversion of Exercise of derivative security at price 11.60 - 12.68 per share. | 30K | $362.04K |
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Year |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -35.8 | 26.1 | -7.4 | -3.2 | 1.1 | -4.7 | -7.4 | 6.9 | -4.9 | -14.6 | −43.8% | ||
| 2025 | 16.6 | -9.7 | -13.6 | -26.0 | 109.7 | -22.7 | 15.2 | 12.5 | -33.9 | -1.2 | -27.7 | -13.8 | −42.4% |
| 2024 | 54.9 | 1.0 | -9.4 | 0.2 | -1.2 | -3.7 | 18.4 | 14.5 | 382.6 | -52.8 | -15.3 | -29.1 | +150.5% |
| 2023 | 29.2 | -4.5 | -14.9 | -1.1 | -8.3 | -8.2 | -0.9 | -17.4 | -5.1 | -13.3 | -8.6 | 12.4 | −39.5% |
| 2022 | -32.1 | -7.6 | 0.2 | -34.2 | -15.1 | -23.1 | 22.1 | -7.8 | -6.9 | -31.8 | -59.7 | -52.6 | −96.3% |
| 2021 | -18.1 | -13.3 | 8.5 | -22.1 | 25.2 | -5.2 | 14.0 | 7.9 | -22.2 | −31.8% |
Buy / hold / sell counts
Instil Bio, Inc., a biopharmaceutical company, focuses on identifying and advancing therapeutic opportunities. It seeks to in-license or acquire and develop additional novel therapeutic candidates in diseases with significant unmet medical need. Instil Bio, Inc. was incorporated in 2018 and is headquartered in Dallas, Texas.